|Bid||1.40 x 2400|
|Ask||2.20 x 300|
|Day's Range||1.39 - 1.51|
|52 Week Range||0.95 - 4.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2018 - Mar 16, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||4.00|
When Aralez Pharmaceuticals Inc’s (TSX:ARZ) announced its latest earnings (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...
Categories: Yahoo FinanceGet free summary analysis Aralez Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aralez Pharmaceuticals, Inc. – Horizon Pharma plc, Johnson & Johnson, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie, Inc. and Eli Lilly ... Read more (Read more...)
MISSISSAUGA, Ontario, Nov. 30, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations.
Aralez Pharmaceuticals Inc (TSX:ARZ) is a small-cap stock with a market capitalization of CAD CA$133.77M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...
Aralez (ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary care physicians, and vascular surgeons. During the third quarter of 2017 Aralez reported all-time highs in both new prescriptions (NRx) and total prescriptions (TRx), as they increased 151% and 82%, respectively. Thus far, 65% of Zontivity® prescriptions are written by cardiologists, 24% from primary care physicians, and 4% from vascular surgeons.
NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Sage Therapeutics stole the show on Thursday, with gains of over 50% at the close. The company presented positive data with analysts responding ...
The Milton, Ontario-based company said it had a loss of 37 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
-3Q 2017 Net Revenues of $24.3 Million ; Year-to-Date 2017 Net Revenues of $77.9 Million - -Implements Fiscal Improvements designed to Deliver Profitability, Support Growth & Extend Cash Runway- -Provides ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Aralez Pharmaceuticals Inc (TSX:ARZ) as an investment opportunity. Anyone interestedRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aralez Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ARLZ-US. Comparing the performance and risk of Aralez Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Aralez Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Aralez Pharmaceuticals, Inc. – Horizon Pharma plc, Sanofi Sponsored ADR, Johnson & Johnson, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie, Inc. ... Read more (Read more...)
On August 9, 2017, Aralez Pharmaceuticals Inc. (ARLZ) announced financial results for the second quarter of 2017 and provided a business update. Total revenues for the second quarter of 2017 were $27.6 million, compared to $12.6 million for the second quarter of 2016. The $27.6 million of revenue consisted of $8.8 million in net product revenue, which is derived from the product portfolio acquired from the acquisition of Tribute along with net product revenues for YOSPRALA®, Fibricor®, and Zontivity®, and other revenues of $18.9 million, which were comprised of $3.9 million in royalties from the sale of VIMOVO®, a $4.0 million one time license fee that was recorded in the second quarter in connection with a license agreement signed in May 2017, and net revenues from the Toprol-XL® franchise of $11.0 million.
-2Q 2017 Net Revenues of $27.6 Million , a $15.0 Million Increase Compared to 2Q 2016- -First Half 2017 Net Revenues of $53.6 Million , a $33.0 Million Increase Compared to First Half 2016- MISSISSAUGA, ...
-Executive Management to Host Conference Call on August 9, 2017 at 9:00 a.m. ET - MISSISSAUGA, Ontario , July 24, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced ...
On June 7, 2017, Aralez (ARLZ) announced the national commercial launch of Zontivity® in the U.S. The company had previously commenced a phased launch of Zontivity® in late April 2017 with 15 sales representatives targeting high volume physicians who treat post-myocardial infarction and peripheral artery disease (PAD) patients. As the following figure shows, the phased launch was very successful with 98% growth in new prescriptions (NRx) after five weeks, compared to the five weeks preceding the phased launch. The company’s full sales force (approximately 75 representatives) is now promoting Zontivity® to approximately 12,000 cardiologists, primary care physicians, and vascular surgeons.
LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), following which we ...
Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents
-Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories, Mylan, and Lupin- MISSISSAUGA, Ontario , June 27, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ...
MISSISSAUGA, Ontario, June 7, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) (Aralez or the Company) today announced the national commercial launch of Zontivity® (vorapaxar) in the U.S. will commence this week. Zontivity is the only antiplatelet therapy that inhibits PAR-1-mediated platelet aggregation in response to thrombin.